UK-headquartered Beacon Therapeutics has raised a whopping $170 million in second-round financing that will be used to advance a gene therapy for an inherited cause of blindness through a pivotal trial.The Series B – led by Forbion and joined by other investors including Syncona, Oxford Science Enterprises and Oxford University Innovation – takes the total raised by Beacon since its formation last year to $290 million, making it a rising star on the UK life sciences scene.
